bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
158 hedge funds and large institutions have $134M invested in bluebird bio in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 61 increasing their positions, 41 reducing their positions, and 54 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 41
3.35% less ownership
Funds ownership: 6.02% → 2.67% (-3.3%)
16% less funds holding
Funds holding: 187 → 158 (-29)
26% less capital invested
Capital invested by funds: $182M → $134M (-$48M)
41% less call options, than puts
Call options by funds: $1.48M | Put options by funds: $2.49M
52% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.94M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.66M |
| 3 |
Millennium Management
New York
|
+$3.62M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.4M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$7.85M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$7.25M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$5.51M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$4.35M |
BLUE Hedge Fund Activity: Q1 2024 in Review
158 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2024, worth a combined $134M — down 26% from $182M a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of BLUE and 26 opened new positions — a net loss of 28 holders — while 41 trimmed existing stakes and 61 added.
The largest buyer was BlackRock, adding an estimated $7.94M. The largest seller was State Street, cutting an estimated $13.4M.
- 158 institutional investors held bluebird bio (BLUE) as of Q1 2024, down from 187 in Q4 2023.
- Funds reported $134M of bluebird bio stock for Q1 2024, down 26% quarter-over-quarter.
- 26 funds opened new bluebird bio positions in Q1 2024 and 54 closed out, a net change of -28 holders.
- The largest bluebird bio buyer in Q1 2024 was BlackRock, an estimated $7.94M added.
- The largest bluebird bio seller in Q1 2024 was State Street, an estimated $13.4M sold.
Based on aggregated 13F filings for Q1 2024.